Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality ...

A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid ...

TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the ...

Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of ...

A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a time.

The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ...

SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver ...

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian ...

Breast MRI helps doctors detect disease in newly diagnosed and high-risk patients without replacing mammograms, according to ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...